Cargando…

Zhou Z, Nath R, Cerny J, et al. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Adv. 2020;4(13):3180-3190.

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2021
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270564/ https://www.ncbi.nlm.nih.gov/pubmed/34242389 http://dx.doi.org/10.1182/bloodadvances.2021005193

Ejemplares similares

Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
por: Rodriguez, Tulio E., et al.
Publicado: (2016)

Busulfan plus melphalan versus high-dose melphalan as conditioning regimens in autologous stem cell transplantation for newly diagnosed multiple myeloma
por: Byun, Ja Min, et al.
Publicado: (2018)

Busulfan plus melphalan versus melphalan alone conditioning regimen after bortezomib based triplet induction chemotherapy for patients with newly diagnosed multiple myeloma
por: Park, Songyi, et al.
Publicado: (2021)

Variable gain amplifier (PS/RF-HC 3190)
por: Paoluzzi, M
Publicado: (1996)

Variable gain amplifier (ps/rf-hc 3190)
por: Paoluzzi, M
Publicado: (1996)

Busulfan and melphalan as conditioning regimen for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia in first complete remission
por: Bueno, Nadjanara Dorna, et al.
Publicado: (2011)

P1390: THE EFFICACY AND SAFETY OF MODIFIED MELPHALAN AND BUSULFAN-BASED REGIMEN FOR ALLOGENEIC TRANSPLANTATION IN REFRACTORY/RELAPSED AML PATIENTS
por: Chen, S., et al.
Publicado: (2022)

Busulfan/Cyclophosphamide Compared with Melphalan as a Conditioning Regimen for Autologous Transplantation of Multiple Myeloma: A Long-Term Assessment
por: Zhou, Shiyuan, et al.
Publicado: (2023)

Conditioning regimen using busulfan plus melphalan in hematopoietic stem cell transplantation: can this conditioning regimen be used in autologous or allogeneic transplantation for acute leukemia?
por: Lemoli, Roberto M., et al.
Publicado: (2011)

PB2411: THE EFFICACY OF MODIFIED MELPHALAN AND BUSULFAN-BASED CONDITIONING REGIMEN FOR AUTOLOGOUS-HSCT IN LOW-RISK AND INTERMEDIATE-RISK AML PATIENTS
por: Zhai, Weihua, et al.
Publicado: (2023)

P1298: THE EFFICACY AND SAFETY OF MODIFIED MELPHALAN AND BUSULFAN-BASED CONDITIONING REGIMEN FOR ALLOGENEIC-HSCT IN REFRACTORY/RELAPSED OR PERSISTENT MRD POSITIVITY AML PATIENTS
por: Jiang, Erlie, et al.
Publicado: (2023)

Long-term outcomes of busulfan plus melphalan-based versus melphalan 200 mg/m(2) conditioning regimens for autologous hematopoietic stem cell transplantation in patients with multiple myeloma: a systematic review and meta-analysis
por: Gao, Fei, et al.
Publicado: (2021)

Phase 2 Clinical Trial of High-Dose Gemcitabine/Busulfan/Melphalan for Autologous Stem-Cell Transplantation in Relapsed/Refractory Myeloma: Matched-Pair Comparison with Melphalan
por: Nieto, Yago, et al.
Publicado: (2017)

Pasquini MC, Hu Z-H, Curran K, et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020;4(21):5414-5424.
Publicado: (2022)

Satyendra Nath Bose: his life and times
por: Wali, Kameshwar C
Publicado: (2009)

Dr Sambhu Nath De: unsung hero
por: Nair, G. Balakrish, et al.
Publicado: (2011)

Dhirendra Nath Nandi, FRCP (Edin.) FRCPsych
por: Nandi, Parthasarathi
Publicado: (2018)

Prof. Narender Nath Sood, 1937 – 2022
por: Sihota, Ramanjit, et al.
Publicado: (2022)

Comparison of Melphalan Combined with Treosulfan or Busulfan as High-Dose Chemotherapy before Autologous Stem Cell Transplantation in AML
por: Gurevich, Ekaterina, et al.
Publicado: (2022)

NMDP/CIBMTR donor selection guidelines
Publicado: (2019)

Response to Zhou and Robinson
por: Betel, Doron, et al.
Publicado: (2015)

Reply to Shao and Zhou
por: Gagelmann, Nico, et al.
Publicado: (2022)

Reply to Wang and Zhou
por: Jandl, Katharina, et al.
Publicado: (2023)

Gowin K, Ballen K, Ahn KW, et al. Survival following allogeneic transplant in patients with myelofibrosis. Blood Adv. 2020;4(9):1965-1973.
Publicado: (2021)

Völker LA, Kaufeld J, Miesbach W, et al. Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood Adv. 2020;4(13):3085-3092.
Publicado: (2022)

Cases Reported by Assistant-Surgeon Devendra Nath Roy
Publicado: (1879)

Surgical Cases from the Sambhu Nath Pundit Hospital
por: Brown, E. Harold
Publicado: (1901)

Influenza as Observed in the Sambhu Nath Pundit Hospital, Calcutta
por: Sen, Debendra Nath
Publicado: (1920)

Adverse Effects of Busulfan Plus Cyclophosphamide versus Busulfan Plus Fludarabine as Conditioning Regimens for Allogeneic Bone Marrow Transplantation
por: Mehdizadeh, Mahshid, et al.
Publicado: (2021)

Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial
por: Seydoux, Claire, et al.
Publicado: (2020)

Surgical Cases: Treated in the Sambhu Nath Pandit Hospital, Calcutta
por: Crawford, D. G.
Publicado: (1899)

Surgical Cases: Treated in the Sambhu Nath Pandit Hospital, Calcutta
por: Crawford, D. G.
Publicado: (1899)

Professor Sir Ram Nath Chopra and the Growth of Pharmacology in India
por: Paranjpe, A. S.
Publicado: (1944)

Pran Nath Nagpal – The little master with a big footprint
por: Agnihotri, Prashant
Publicado: (2022)

ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR NEUROBLASTOMA: THE CIBMTR EXPERIENCE
por: Hale, Gregory A., et al.
Publicado: (2013)

Kahn JM, Brazauskas R, Tecca HR, et al. Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases. Blood Adv. 2020;4(9):2084-2094.
Publicado: (2022)

Surgical Cases from the Sambhu Nath Pandit Hospital, Bhowanipur, Calcutta
por: Brown, E. Harold
Publicado: (1901)

Surgical Cases from the Sambhu Nath Pandit Hospital, Bhowanipur, Calcutta
por: Brown, E. Harold
Publicado: (1901)

Jitendra Nath Pande (14.06.1941 - 23.05.2020)
por: Khilnani, Gopi C
Publicado: (2020)

MiR-3180 inhibits hepatocellular carcinoma growth and metastasis by targeting lipid synthesis and uptake
por: Hong, Jie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lt5alnaovrmca7i3pbr9pa23pu